TRANS GENIC Receives Milestone Payment for In-vitro Diagnostic Agent using GANP Mouse Technology

TRANS GENIC INC. (CEO: Kenji Fukunaga, Fukuoka City, Fukuoka, Japan, “TRANS GENIC”) today announced that, it has received a notification from global healthcare company (“Company A”) that in-vitro diagnostic agent using specific antibody developed by GANP® mouse technology was launched onto market. Consequently, TRANS GENIC will receive the milestone payment and royalties according to the sales amount from Company A in accordance with licensing agreement.

[Overview]
TRANS GENIC strongly promotes the licensing business associated with GANP mouse technology. As part of this strategy, TRANS GENIC entered into exclusive worldwide license agreement with Company A on the manufacturing and distribution of in-vitro diagnostic agent using specific antibody developed by GANP mouse technology on December 21, 2015.

This milestone payment will be paid for launching in-vitro diagnostic agent onto the market in Japan. This is the second case that TRANS GENIC’s licensing business of GANP mouse technology was turned to practical use.

TRANS GENIC will receive the milestone payments and royalties according to the sales amount under the license agreement. However, specific amount cannot be disclosed because of the contractual issue.

This receipt of milestone payment will not have a material impact on the financial performance for FY2019. TRANS GENIC will promote the licensing business of useful seed assets for the future growth of earning and corporate value.

Contact for inquiries:
TRANS GENIC INC.
Yutaka Funabashi, Director
Telephone +81-(0)3-6551-2601